3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
7
Neoplasms
5
Neoplasm Metastasis
5
Adenocarcinoma of Lung
5
Melanoma
3
Glioblastoma
3
Carcinoma
3
cMET-dysregulated Advanced Solid Tumors
2
Sarcoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
cMET Dysegulation Advanced Solid Tumors
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Noonan Syndrome 6
1
Neuroblastoma
1
Malignant Non-small Cell Neoplasm of Lung Stage IV
1
Lymphoproliferative Disorders
1
Liver Neoplasms
1
Laryngeal Diseases
1
Kidney Neoplasms
1
Hepatic Impairment
1
Glioma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Interventions
Cyclophosphamide
9
Pemetrexed
6
pembrolizumab
5
fludarabine
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
ponatinib
4
atezolizumab
4
Rituximab
4
Dexamethasone
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
Sunitinib
3
Melphalan
3
Doxorubicin
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
pomalidomide
2
osimertinib
2
napabucasin
2
isatuximab
2
fludarabine phosphate
2
ficlatuzumab
2
entrectinib
2
entinostat
2
durvalumab
2
cobimetinib
2
capmatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Histologic Type
×
capmatinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled